Dona Ferentes
Abrió la caja, vio al gatito, y sonrió
- Joined
- 11 January 2016
- Posts
- 15,586
- Reactions
- 21,191
CSL results out. I'll leave it to market to price.. now $263.
• Revenue $13.31 billion, up 31% at CC
• NPAT $2.19 billion, down 3%
• NPAT $2.44 billion at CC, up 8%
• NPATA $2.61 billion, up 10%
• NPATA $2.86 billion at CC, up 20%
• NPATA earnings per share $5.412, up 6%
• NPATA earnings per share $5.92 at CC up 17%
• Final dividend of US$1.29 per share
o Total full year dividend US$2.36, up 6%
o Converted to Australian currency, the total full year dividend is approximately A$3.59 per share, up 13%
• NPATA for FY24 is anticipated to be in the range of approximately $2.9 billion to $3.0 billion at CC
- FY23 reported NPATA US$2.61 billion
- Up 20% at constant currency
- Strong Ig growth
- Record level of plasma collections
- CSL Vifor integration well advanced
- Successful launch of gene therapy HEMGENIX®
• Revenue $13.31 billion, up 31% at CC
• NPAT $2.19 billion, down 3%
• NPAT $2.44 billion at CC, up 8%
• NPATA $2.61 billion, up 10%
• NPATA $2.86 billion at CC, up 20%
• NPATA earnings per share $5.412, up 6%
• NPATA earnings per share $5.92 at CC up 17%
• Final dividend of US$1.29 per share
o Total full year dividend US$2.36, up 6%
o Converted to Australian currency, the total full year dividend is approximately A$3.59 per share, up 13%
• NPATA for FY24 is anticipated to be in the range of approximately $2.9 billion to $3.0 billion at CC